Preparation and in vitro and in vivo release studies of Huperzine A loaded microspheres for the treatment of Alzheimer's disease

Journal of Controlled Release

Volumn 107, Issue 3, 2005, Pages 417-427

  Liu, W H ^a   Song, J L ^a   Liu, K ^a   Chu, D F ^a   Li, Y X ^a  

^a YANTAI UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Biodegradable polyester; Huperzine A; Microspheres; Spray drying

Indexed keywords

DISEASE CONTROL; DISEASES; DRUG PRODUCTS; MOLECULAR WEIGHT; PATIENT TREATMENT; POLYESTERS;

ALZHEIMER'S DISEASE; BIODEGRDABLE POLYESTERS; HYPERZINE A; MICROSPHERES; SPRAY DRYING;

CONTROLLED DRUG DELIVERY;

HUPERZINE A; MICROSPHERE; POLYGLACTIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ARTICLE; BIODEGRADABILITY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG RELEASE; DRUG SYNTHESIS; ENCAPSULATION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; SPRAY DRYING;

ALZHEIMER DISEASE; ANIMALS; CHOLINESTERASE INHIBITORS; DESICCATION; DOGS; DRUG COMPOUNDING; DRUG STABILITY; LACTIC ACID; MICROSCOPY, ELECTRON, SCANNING; MICROSPHERES; NEUROPROTECTIVE AGENTS; PARTICLE SIZE; POLYGLYCOLIC ACID; POLYMERS; SESQUITERPENES; SOLUBILITY; WATER;

EID: 25844439321     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2005.03.025     Document Type: Article

References (27)

1. Alzheimer's disease-Unraveling the Mystery; U.S. Department of Health and Human Services, National Institutes of Health, NIH Publication Number: 02-3782, October 2002.
2. Alzheimer's Disease Fact Sheet; U.S. Department of Health and Human Services, Public Health Service National Institutes of Health National Institute on Aging, NIH Publication No. 03-3431, February 2003, (3).
3. S.T. Dinsmore Treatment options for Alzheimer's disease J. Am. Osteopath. Assoc. Suppl. 9 1999 6 8
4. R.S. Doody Current treatments for Alzheimer's disease: cholinesterase inhibitors J. Clin. Psychiatry 64 Suppl. 9 2003 11 17
5. J.J. Sramek, and N.R. Cutler Recent developments in the drug treatment of Alzheimer's disease Drug Aging 14 1999 359 373
6. M. Abramowicz Tacrine for Alzheimer's disease Med. Lett. Drugs Ther. 35 1993 87 88
7. S.S. Xu, Z.Y. Cai, Z.W. Qu, R.M. Yang, Y.L. Cai, G.Q. Wang, X.Q. Su, X.S. Zhong, R.Y. Cheng, WA. Xu, J.X. Li, and B. Feng Huperzine-A in capsules and tablets for treating patients with Alzheimer's disease Acta Pharmacol. Sin. 20 6 1999 486 490
8. J.S. Liu, Y.L. Zhu, C.M. Yu, Y.Z. Zhou, Y.Y. Han, F.W. Wu, and B.F. Qi The structures of huperzine A and B, two new alkaloids exhibiting marked anticholinesterase activates Can. J. Chem. 64 1986 837
9. L. Qian, and R. Ji A total synthesis of (±)Huperzine A Tetrahedron Lett. 30 1989 2089
10. M. McKinney, J.H. Miller, F. Yamada, W. Tueckmantel, and A.P. Kozikowski Potencies and stereoselectivities of enantiomers of huperzine A for inhibition of rat cortical acetylcholinesterase Eur. J. Pharmacol. 203 1991 303
11. A.P. Kozikowski, E. Thiels, X.C. Tang, and I. Hanin B.E. Maryanoff C.A. Maryanoff Advances in Medicinal Chemistry vol. 1 1992 JAI Press Greenwich, CT 175
12. S.S. Xu, Z.X. Guo, Z. Wang, Z.M. Du, W.A. Xu, and J.S. Yang Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease Acta Pharmacol. Sin. 16 1995 391 395
13. S.S. Xu, H.B. Xie, Z.M. Du, Z.H. Tong, Q.C. Shi, and K.M. Lu Efficacy of tablet huperzine-A on memory and cognition in patients with benign senescent forgetfulness China J. Clin. Pharm. Ther. 2 1997 1 4
14. Q.Q. Sun, S.S. Xu, J.L. Pan, H.M. Guo, and W.Q. Cao Huperzine-A capsules enhance memory and learning performance in 34 pairs of matched adolescent students Acta Pharmacol. Sin. 20 7 1999 601 603
15. Z.X. Zhang, X.D. Wang, Q.T. Chen, L. Shu, J.Z. Wang, and G.L. Shan Clinical efficacy and safety of Huperzine A in treatment of mild to moderate Alzheimer's disease, a placebo-controlled, double-blind, randomized trial Natl. Med. J. China 82 2002 941 944
16. Y.B. Jiang, C.S. Huang, and L.A. Huang Improvement in cognition ability and action drawback of Alzheimer disease treated by huperzine A Clin. Med. China 18 2002 802 803
17. K.M. Hwang, S.Y. Liu, Transdermal rate-controlled delivery of Huperzine A for treatment of Alzheimer's disease, US Patent 6,352,715 (2002).
18. H. Okada One- and three-month release injectable rnicrospheres of the LH-RH superagonist leuprorelin acetate Adv. Drug Deliv. Rev. 28 1997 43 70
19. D. Bodmer, T. Kissel, and E. Traechslin Factors influencing the release of peptides and proteins from biodegradable parenteral depot systems J. Control. Release 21 1992 129 138
20. Lunelle® Monthly injection suspension; Pharmacia and Upjohn, http://www.fda.gov/cder/foi/label/2000/20874lbl.pdf.
21. P.B. Deasy Microencapsulation and Related Drug Process 1984 Marcel Dekker Inc New York
22. D.H. Lewis Controlled release of bioactive agents from lactide/glycolide polymers M. Chasin R. Langer Biodegradable Polymers as Drug Delivery Systems 1990 Marcel Dekker Inc New York 1 42
23. Q. Yang, D. Williams, G. Owusu-Abobio, N.K. Ebube, and M.J. Habib Controlled release tacrine delivery system for the treatment of Alzheimer's disease Drug Deliv. 8 2001 93 98
24. R.A. Jain The manufacturing techniques of various drug biodegradable poly(lactide-co-glycolide) (PLGA) devices Biomaterials 21 2000 2475 2490
25. T. Kissel, Z. Brich, S. Bantle, L. Lancanjan, F. Nimmerfall, and P. Vit Parenteral depot-systems on the basis of biodegradable polyesters J. Control. Release 16 1991 27 42
26. M. Vert, S. Li, and H. Garreau More about the degradation of LA/GA derived matrices in aqueous media J. Control. Release 16 1991 15 26
27. K. Maeder, B. Gallez, K.J. Liu, and H.M. Swartz Noninvasive in vivo characterization of release processes in biodegradable polymers by low frequency electron paramagnetic resonance spectroscopy Biomaterials 17 1996 459 463